Latest News - Zoetis
Top Corporates Hub
Zoetis
Zoetis: Sentiment Keeps Winning As Fundamentals Improve
24.07.2026 08:00
Zoetis stock trades ~45% below fair value, despite resilient earnings, a low forward P/E, and a 2.8% dividend yield. Learn more. Click for more on ZTS stock.
Temporary Concerns Present Entry Point in Zoetis (ZTS)
23.07.2026 14:34
Moon Capital Management, LLC, an investment management company, released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 index rebounded in the second quarter, achieving a 9.6% return for the first half of the year, while Moon Capital Management’s equity portfolio gained 4%. AI-related stocks led […]
Zoetis Inc (NYSE:ZTS): A Top Value Stock with Undervalued Strength
20.07.2026 12:20
Zoetis (ZTS) offers a rare value opportunity with a P/E of 11.83, top-tier profitability, steady growth, and strong cash flow—a compelling buy for disciplined value investors.
Zoetis: An Attractive Risk-Reward Opportunity
17.07.2026 06:33
We have long viewed Zoetis as one of the highest-quality businesses in healthcare, and the company has generally been valued accordingly.
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
15.07.2026 12:30
PARSIPPANY, N.J., July 15, 2026--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, w
A Dividend Portfolio That Pays For Your Pets
10.07.2026 16:30
Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and some stretch past 18. The bill that comes with that lifespan is the part many owners never total, because the monthly receipts feel ... A Dividend Portfolio That Pays For Your Pets
Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
07.07.2026 11:00
PARSIPPANY, N.J., July 07, 2026--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose.
Deadly Screwworm’s Leap Into the US Mystifies Health Experts
06.07.2026 11:00
(Bloomberg) -- As the deadly New World screwworm spreads through Texas, posing significant risk to the US cattle herd, experts are still puzzling over the mystery of how it got there.Most Read from BloombergGreece Offers Bounty to Catch Ravenous Fish Lured by Warming SeaOil, Gas Tankers Cross Hormuz Via Oman-Side Route After U-TurnsThe Tanker Tycoon Making Millions on Hormuz Shuttle RunsModi’s Flagship Biofuel Push Faces Backlash From MotoristsOil’s Supply Wave, Tumbling Prices Rekindle Fears of
Zoetis Inc (NYSE:ZTS) Offers High-Quality Dividend Growth and Strong Profitability at a Discount
03.07.2026 11:40
Zoetis offers a reliable 1.64% dividend yield with strong safety and 20.56% annual growth. Backed by stellar profitability and a cheap P/E of 11.56, ZTS is a top-tier dividend stock for income-focused investors.
Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
01.07.2026 13:15
On June 27, 2026, Zoetis Inc. was removed from several Russell Top 200 indexes and simultaneously added to the Russell Midcap Index and its value and growth benchmarks, reflecting a shift in how the company is classified within major equity indices. This index reclassification comes amid weaker demand for key osteoarthritis treatments, intensifying competition, and pending securities class actions that have focused attention on Zoetis’s risk profile and business momentum. Against this...
This Analyst Thinks Stabilization For Zoetis’ Products ‘Could Be Several Quarters Away’
01.07.2026 10:59
Barclays’ latest commentary on Zoetis comes in the aftermath of Zoetis’ first-quarter earnings, which it described as “challenging.”
Neogen: Still A Difficult Story
27.06.2026 09:41
Neogen has addressed urgent deleveraging needs through divestments and cost-cutting, but earnings power remains modest. See why NEOG stock is a hold.
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
23.06.2026 13:42
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2 Reasons to Like ZTS and 1 to Stay Skeptical
22.06.2026 15:23
Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Zoetis (ZTS) Lost 22% in a Day; What Has Wall Street Worried?
22.06.2026 13:30
With a short percentage of shares outstanding of 3.21%, Zoetis Inc. (NYSE:ZTS) is among the 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue. On May 27, Argus downgraded Zoetis Inc. (NYSE:ZTS) from Buy to Hold following a sharp decline in the company’s share price. The research firm pointed to a steep 22% single-day drop […]
What Makes Zoetis (ZTS) an Attractive Bet?
17.06.2026 14:16
Renaissance Investment Management, an investment management company, released its Q1 2026 “Large Cap Growth Strategy.” A copy of the letter can be downloaded here. Stocks fell sharply in the first quarter due to the Iran conflict. The Energy and Materials sectors outperformed, Financials and Consumer Discretionary lagged. Large-cap stocks underperformed smaller-cap stocks, and Value outperformed Growth. […]
Should You Continue to Hold PAHC Stock in Your Portfolio?
15.06.2026 12:52
Phibro Animal Health gains from Animal Health strength and Zoetis MFA integration, but macro and FX headwinds remain as the stock rises 27.6% over the past year.
Zoetis Might Be Cheap For A Reason
11.06.2026 00:48
Zoetis (ZTS) is down ~70% and trades at low multiples. Weak U.S. Companion Animal segment prompted a downwardly revised 2026 outlook. See more here.
Chewy Earnings Are Unremarkable. The Stock Is Sharply Higher Anyway.
10.06.2026 11:26
Shares of the pet supplies retailer rise after Chewy posts first-quarter adjusted earnings that meet expectations.
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 We Brush Off
09.06.2026 12:30
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.